Point72 Asset Management, L.P.
Position in NMRA — Neumora Therapeutics, Inc.
CIK 1603466
STAMFORD, CT
Position in NMRA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$1,174,685
-$5,401,486 QoQ
Shares Held
602,403
-83.6% QoQ
Ownership
0.321%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
4 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NMRA Over Time
Shares Held
Position Value (USD)
Derivatives in NMRA
reported options exposure · as of Dec 31, 2024CallValue
$0
CallShares
0
PutValue
$15,900,000
PutShares
1,500,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Point72 Asset Management, L.P. holds $2,243,264,515 across 171 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
4,473,478 | $158,316,386 | |
| 2 | CYTK |
Cytokinetics Inc
|
1,587,712 | $135,257,185 | |
| 3 | BBIO |
BridgeBio Pharma, Inc.
|
1,525,782 | $113,640,243 | |
| 4 | AXSM |
Axsome Therapeutics, Inc.
|
416,516 | $101,950,621 | |
| 5 | LEGN |
Legend Biotech Corp
|
3,076,124 | $88,838,461 | |
| 6 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
137,029 | $73,577,721 | |
| 7 | CELC |
Celcuity Inc.
|
650,916 | $68,098,831 | |
| 8 | ACAD |
Acadia Pharmaceuticals Inc
|
2,433,168 | $61,559,150 |
All Filings in NMRA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,174,685 | 602,403 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $6,576,171 | 3,673,839 | Shares | Defined | 2026-02-17 | |
| 2024-12-31 | $15,900,000 | 1,500,000 | Put | Defined | 2025-02-14 | |
| 2024-09-30 | $1,097,447 | 83,077 | Shares | Defined | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||